Abstract：
People with immune deficiency are at risk of developing infections caused by several bacterial and fungal species. In this work, chitosan-coated miconazole was developed by a simple sol-gel method. Miconazole is considered an effective drug to treat vaginal infection-causing bacteria and fungi. The coating of chitosan with miconazole nitrate showed the highest drug loading efficiency (62.43%) and mean particle size (2 μm). FTIR spectroscopic analysis confirmed the entrapment of miconazole nitrate into chitosan polymer. The antifungal result demonstrated that MN@CS microgel possessed notable anti-Aspergillus fumigatus and Candida albicans activity in lower doses. Antibacterial activity results revealed excellent bacterial growth inhibition of MN@CS microgel towards human skin infectious pathogens Escherichia coli and Staphylococcus aureus. The biocompatibility studies of In vitro cell viability and Artemia salina lethality assay suggested that MN@CS microgel is more biosafe and suitable for human external applications. In the future, it will be an efficient anti-inflammatory agent for the treatment of vaginal infections.
摘要：
患有免疫缺陷的人有发生由几种细菌和真菌引起的感染的风险。在这项工作中,壳聚糖包被咪康唑是通过简单的溶胶-凝胶法开发的。咪康唑被认为是治疗引起阴道感染的细菌和真菌的有效药物。壳聚糖与硝酸咪康唑涂层显示最高的载药率（62.43％）和平均粒径（2μm）。FTIR光谱分析证实硝酸咪康唑截留在壳聚糖聚合物中。结果表明，在较低剂量下，MN@CS微凝胶具有明显的抗烟曲霉和白色念珠菌活性。抗菌活性结果表明，MN@CS微凝胶对人皮肤感染性病原体大肠杆菌和金黄色葡萄球菌具有优异的细菌生长抑制作用。体外细胞活力和卤虫致死性实验的生物相容性研究表明，MN@CS微凝胶更具有生物安全性，适用于人体外部应用。在未来,它将是治疗阴道感染的有效抗炎药。
